SiliconInvestor
     Advanced Search   [ sign in ]

sponsor
Sponsor

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Icebrg who wrote (13135)9/27/2004 3:05:34 PM
From: Biomaven of 40248
 
We have also the question whether the ability to receive more doses can be considered as a good indicator for an increase in the length of survival

Hard to see how it isn't a good proxy. Certainly the patients in this trial seem to be doing better than patients in previous trials - but (as always) we don't really know if it's because of the drug or because the patient population is somehow different. (I think it's likely the drug).

Thanks for the update Erik - much appreciated.

Peter
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.